M. Bafadhel (Oxford (Oxfordshire), United Kingdom), A. Papi (Ferrara, Italy)
Late Breaking Abstract - COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS
K. Rabe (Grosshansdorf, Germany), F. Martinez (New York, NY, United States of America), G. Ferguson (Farmington Hills, MI, United States of America), D. Singh (Manchester, United Kingdom), J. Wedzicha (London, United Kingdom), M. Jenkins (Cambridge, United Kingdom), M. Aurivillius (Gothenburg, Sweden), C. Reisner (Morristown, NJ, United States of America), P. Dorinsky (Durham, NC, United States of America)
|     |
Late Breaking Abstract - Real-world evidence of dual bronchodilator therapy using Clinical COPD Questionnaire in 4700 COPD patients
A. Valipour (Wien, Austria), S. Avdeev (Moscow, Russian Federation), A. Barczyk (Katowice, Poland), V. Bayer (Ridgefield, United States of America), Z. Fridlender (Jerusalem, Israel), M. Georgieva (Vidin, Bulgaria), O. Kudela (Hradec Králové, Czech Republic), A. Medvedchikov (Wien, Austria), R. Miron (Iasi, Romania), M. Sanzharovskaya (Wien, Austria), V. Šileikiene (Vilnius, Lithuania), J. Šorli (Topolšica, Slovenia), M. Spielmanns (Wald, Switzerland), Z. Szalai (Gyor, Hungary)
| |
Prevalence and abundance of selected genes conferring macrolide resistance genes in COPD patients during maintenance treatment with azithromycin
R. Djamin (Breda, Netherlands), S. Talman (Breda, Netherlands), E. Schrauwen (Breda, Netherlands), C. Von Wintersdorff (Maastricht, Netherlands), P. Wolffs (Maastricht, Netherlands), P. Savelkoul (Maastricht, Netherlands), S. Uzun (Breda, Netherlands), R. Kerstens (Hilvarenbeek, Netherlands), M. Van Der Eerden (Rotterdam, Netherlands), J. Kluytmans (Breda, Netherlands)
| |
The effect of the indicated use of ß-blockers on the risk of COPD exacerbations: the Rotterdam Study
L. Karimi (Rotterdam, Netherlands), G. Brusselle (Ghent, Belgium), L. Lahousse (Ghent, Belgium), P. De Nocker (Ghent, Belgium), B. Stricker (Rotterdam, Netherlands), K. Verhamme (Rotterdam, Netherlands)
| |
Small airway disease (SAD) is associated with respiratory symptoms and relevant for therapy in early COPD
F. Trinkmann (Heidelberg, Germany), J. Schäfer (Mannheim, Germany), F. Trudzinski (Heidelberg, Germany), J. Gawlitza (Mannheim, Germany), J. Saur (Mannheim, Germany), I. Akin (Mannheim, Germany), M. Borggrefe (Mannheim, Germany), T. Ganslandt (Mannheim, Germany), F. Herth (Heidelberg, Germany), R. Buhl (Mainz, Germany)
| |
Predictive modelling of COPD exacerbation rates using baseline risk factors
D. Singh (Manchester, United Kingdom), F. Martinez (New York, NY, United States of America), K. Rabe (Grosshansdorf, Germany), J. Hurst (London, United Kingdom), M. Bafadhel (Oxford, United Kingdom), M. Jenkins (Cambridge, United Kingdom), P. Dorinsky (Durham, NC, United States of America), P. Darken (Morristown, NJ, United States of America)
| |
Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients
P. Rogliani (Roma (RM), Italy), J. Ora (Roma (RM), Italy), A. Girolami (Roma (RM), Italy), I. Rossi (Roma (RM), Italy), M. Cazzola (Roma (RM), Italy), L. Calzetta (Roma (RM), Italy)
| |
Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD
S. Muiser (Groningen, Netherlands), B. Luijk (Utrecht, Netherlands), G. Braunstahl (Rotterdam, Netherlands), I. Heijink (Groningen, Netherlands), H. Reddel (Sydney, Australia), H. Kerstjens (Groningen, Netherlands), M. Van Den Berge (Groningen, Netherlands)
| |
Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial
G. Ferguson (Farmington Hills, MI, United States of America), K. Rabe (Grosshansdorf, Germany), F. Martinez (New York, NY, United States of America), C. Wang (Beijing, China), D. Singh (Manchester, United Kingdom), J. Wedzicha (London, United Kingdom), R. Trivedi (Durham, NC, United States of America), E. St Rose (Morristown, NJ, United States of America), S. Ballal (Morristown, NJ, United States of America), J. Mclaren (Gaithersburg, MD, United States of America), P. Darken (Morristown, NJ, United States of America), M. Aurivillius (Gothenburg, Sweden), C. Reisner (Morristown, NJ, United States of America), P. Dorinsky (Durham, NC, United States of America)
| |